|
PerFix Reagent Kits From Beckman Coulter Life Sciences Deliver Probes …
BioResearch Online (press release) PerFix-Expose1 and PerFix-nc1, innovative new reagent kits for intracellular staining from Beckman Coulter Life Sciences, minimize sample manipulation for a streamlined workflow that delivershigh quality results. Developed for use on Beckman Coulter’s … |
|
他克莫司缓释胶囊获FDA批准
汉丰网 本报讯 安斯泰来美国子公司近日宣布，其他克莫司缓释胶囊（ASTAGRAF XL）获美国食品药品管理局（FDA）批准，与霉酚酸酯（MMF）及皮质类醇联用、结合或不结合巴利昔单抗（basiliximab），用于预防成人肾移植受者的器官排斥 … |
Oncobiologics and InVentive Health Clinical Form Biosimilars PactPharmaceutical Technology MagazineThe current biosimilar assets include generic versions of Humira (adalimumab), Rituxan (rituximab), Avastin (bevacizumab), Herceptin (trastuzumab), and E…
SPECTRUM PHARMACEUTICALS, INC. : Spectrum Pharmaceuticals Reports …4-traders (press release)The ZEVALIN therapeutic regimen consists of two components: rituximab, and Yttrium-90 (Y-90) radiolabeled ZEVALIN for therapy. ZEVALIN builds on the combined …
Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic …7thSpace Interactive (press release)Exclusion criteria included disease exacerbation within past 30 days; rituximab or cyclophosphamide within 6 months; pregnancy. Vaccine …
|
Mainstreaming ME Research: The 8th Invest in ME International ME Conference …
ProHealth For it’s the growing recognition that immune treatments like Rituximab and Ampligen are having dramatic effects on many patients who were once bedbound and without hope, together with two decades of often confusing but highly suggestive research … |
|
Oakland County cancer doctor accused of unnecessary treatments, defrauding …
Detroit Free Press In one case, the federal complaint outlines, Fata prescribed 56 doses of rituximab to a non-Hodgkin’s lymphoma patient over two years, when the norm would be a dozen in two years. In another instance cited in the complaint, Fata allegedly forced a sick … |
OncLiveThe Antibody Arsenal: More Complex Targeted Agents Primed for Increased …OncLiveMore than a century has passed since the discovery of antibodies and thanks to a number of Nobel Prize-winning scientists, we have begun to realize their potential…
|
Top Rated Report : Global Evolving Market for Biosimilar Opportunities …
SBWire (press release) In terms of revenue, six of the top ten pharmaceutical therapies are biological products, which have been targeted by biosimilar developers: Abbvie’s Humira (adalimumab), Roche’s MabThera (rituximab), Herceptin (trastuzumab) and Avastin (bevacizumab), … |
|
Apexigen lands $20M round as China biotech partners advance antibodies
FierceBiotech A startup drug developer with close ties to China’s biotech industry has landed a $20 million A round to push ahead with its clinical development work on antibodies that can help fight off cancer and inflammatory diseases. Apexigen, a Burlingame, CA … Apexigen Secures $20 Million Series A1 FinancingPR Newswire (press release) |